Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × OTHER_GOV × enzalutamide × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 3 OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 1

Interventions

Bevacizumab 4 Zoledronic Acid 3 spartalizumab 2 anlotinib 2 Radiotherapy 2 Positron Emission Tomography Computed Tomography 2 Metformin 2 Letrozole 2 Drug Therapy 2 Cisplatin 2 Capecitabine 2 vosaroxin 1 venetoclax 1 pembrolizumab 1 enzalutamide 1 empagliflozin 1 atezolizumab 1 abiraterone 1 XELOX 1 Vacuum Curettage 1 Tyrosine Kinase Inhibitors 1 Tuberculin 1 Sorafenib 1 Sodium Chloride 1 Radiosurgery 1 Prednisone 1 Prednisolone 1 Poly(ADP-ribose) Polymerase Inhibitors 1 Paclitaxel 1 Neoadjuvant Therapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00268476 2023-04-18

STAMPEDE

Medical Research Council

Phase 2/3 Active not recruiting

11,992 enrolled

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡